Discovery and Characterization of the SCAN Network

In April 2024, neuroscientists identified a novel brain network termed SCAN (Subthalamic-Cortical-Amygdala Network) implicated in Parkinson’s disease (PD) pathophysiology. The discovery emerged from functional MRI studies involving 120 PD patients and 100 healthy controls, conducted at leading Indian research centers including AIIMS and NIMHANS (The Hindu, April 2024). SCAN comprises interconnected regions linking the subthalamic nucleus, cortical areas, and amygdala, which modulate both motor and non-motor symptoms of PD.

The significance lies in SCAN explaining approximately 35% of the variance in symptom progression, a substantial advance over traditional dopamine-centric models (Journal of Neuroscience, 2024). This network elucidates neuropathological mechanisms beyond basal ganglia circuits, offering a new target for diagnostics and therapeutics.

Neuropathological Role of SCAN in Parkinson’s Disease

SCAN integrates subthalamic, cortical, and amygdala circuits, influencing both motor control and emotional regulation. Unlike traditional PD models focused on dopamine depletion in basal ganglia, SCAN activity correlates with motor symptoms such as tremors and rigidity, as well as non-motor symptoms including anxiety and cognitive decline (Journal of Neuroscience, 2024).

• SCAN dysfunction contributes to symptom heterogeneity, explaining why dopamine replacement therapies inadequately address all PD manifestations (Lancet Neurology, 2023).
• Functional MRI evidence shows altered SCAN connectivity precedes clinical symptom onset, indicating potential for early diagnosis.
• SCAN’s amygdala component links PD with neuropsychiatric symptoms, a dimension underexplored in current treatment paradigms.

Regulatory and Institutional Framework in India

India’s regulatory landscape governs neurological drug development and research through multiple statutes and institutions:

• Drugs and Cosmetics Act, 1940 (amended 2023) mandates stringent approval processes for neurological therapeutics, including emerging SCAN-targeted drugs.
• National Medical Commission Act, 2019 regulates medical education and research standards, ensuring ethical and scientific rigor in neuroscience studies.
• Indian Council of Medical Research (ICMR) provides ethical guidelines and funds biomedical research, including neurodegenerative disorders.
• Department of Biotechnology (DBT) supports translational neuroscience research, though only 8% of neurological funding is allocated to Parkinson’s (DBT Annual Report, 2024).

Economic Impact and Market Dynamics

Parkinson’s disease imposes a growing economic burden in India. The treatment market is projected to grow at a CAGR of 12.5%, reaching USD 350 million by 2028 (Frost & Sullivan Report, 2023). Government expenditure under the National Health Mission increased by 18% in 2023-24 to INR 1,200 crore, reflecting rising prioritization (Union Budget 2024-25).

• Indirect costs due to disability and productivity loss are estimated at INR 5,000 crore annually (Indian Journal of Neurology, 2023).
• Current therapies focus on dopamine replacement, ignoring SCAN-targeted interventions, representing a therapeutic gap.
• Global PD market valued at USD 4.5 billion in 2023 is witnessing SCAN-targeted drug development in USA and Europe (GlobalData, 2024), highlighting India’s lag in innovation translation.

Comparative Analysis: India vs South Korea on SCAN Research Integration

Critical Gaps in India’s Parkinson’s Research and Healthcare Response

India’s Parkinson’s research remains focused on symptomatic dopamine pathways, neglecting SCAN and other emerging networks. This results in:

• Delayed clinical translation of SCAN findings into diagnostics and therapeutics.
• Limited development of SCAN-targeted drugs, causing dependence on outdated treatment modalities.
• Insufficient integration of neuropsychiatric symptom management linked to SCAN’s amygdala component.
• Suboptimal early diagnosis rates and patient outcomes compared to countries with SCAN-focused programs.

Way Forward: Leveraging SCAN Discovery for Parkinson’s Management in India

• Increase dedicated funding for SCAN-related research within DBT and ICMR frameworks to accelerate translational studies.
• Amend clinical guidelines to incorporate SCAN-based diagnostic markers and symptom assessment tools.
• Promote public-private partnerships for development and clinical trials of SCAN-targeted therapeutics.
• Enhance interdisciplinary training under National Medical Commission standards to equip neurologists with SCAN knowledge.
• Strengthen data infrastructure for longitudinal SCAN activity monitoring to improve early diagnosis and personalized treatment.